Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

1.

The psychiatric side-effects of rimonabant.

Moreira FA, Crippa JA.

Rev Bras Psiquiatr. 2009 Jun;31(2):145-53. Review.

PMID:
19578688
[PubMed - indexed for MEDLINE]
Free Article
2.

Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.

Gelfand EV, Cannon CP.

Expert Opin Investig Drugs. 2006 Mar;15(3):307-15. Review.

PMID:
16503766
[PubMed - indexed for MEDLINE]
3.

Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.

Moreira FA, Grieb M, Lutz B.

Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44. doi: 10.1016/j.beem.2008.09.003. Review.

PMID:
19285266
[PubMed - indexed for MEDLINE]
4.

Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.

Tucci SA, Halford JC, Harrold JA, Kirkham TC.

Curr Med Chem. 2006;13(22):2669-80. Review.

PMID:
17017918
[PubMed - indexed for MEDLINE]
5.

Rimonabant Sanofi-Synthélabo.

Fernandez JR, Allison DB.

Curr Opin Investig Drugs. 2004 Apr;5(4):430-5. Review.

PMID:
15134285
[PubMed - indexed for MEDLINE]
6.

Cannabinoid receptor CB1 antagonists state of the art and challenges.

Bifulco M, Santoro A, Laezza C, Malfitano AM.

Vitam Horm. 2009;81:159-89. doi: 10.1016/S0083-6729(09)81007-8. Review.

PMID:
19647112
[PubMed - indexed for MEDLINE]
7.

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

Ward SJ, Raffa RB.

Obesity (Silver Spring). 2011 Jul;19(7):1325-34. doi: 10.1038/oby.2011.69. Epub 2011 Apr 7. Review. No abstract available.

PMID:
21475141
[PubMed - indexed for MEDLINE]
8.

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen AJ.

J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x. Review.

PMID:
18426513
[PubMed - indexed for MEDLINE]
9.

Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.

Cox SL.

Drugs Today (Barc). 2005 Aug;41(8):499-508. Review.

PMID:
16234873
[PubMed - indexed for MEDLINE]
10.

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.

Gelfand EV, Cannon CP.

J Am Coll Cardiol. 2006 May 16;47(10):1919-26. Epub 2006 Apr 24. Review.

PMID:
16697306
[PubMed - indexed for MEDLINE]
Free Article
11.

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

Christopoulou FD, Kiortsis DN.

J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x. Review.

PMID:
21198716
[PubMed - indexed for MEDLINE]
12.

The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.

Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB.

J Clin Pharm Ther. 2007 Jun;32(3):209-31. Review.

PMID:
17489873
[PubMed - indexed for MEDLINE]
13.

Rimonabant--a selective CB1 antagonist.

Boyd ST, Fremming BA.

Ann Pharmacother. 2005 Apr;39(4):684-90. Epub 2005 Mar 8. Review.

PMID:
15755787
[PubMed - indexed for MEDLINE]
14.

Effect of antiobesity medications in patients with type 2 diabetes mellitus.

Choussein S, Makri AA, Frangos CC, Petridou ET, Daskalopoulou SS.

Diabetes Obes Metab. 2009 Jul;11(7):641-64. doi: 10.1111/j.1463-1326.2008.01026.x. Epub 2009 Feb 18. Review.

PMID:
19236442
[PubMed - indexed for MEDLINE]
15.

Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.

Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, Santoro A.

Mol Pharmacol. 2007 Jun;71(6):1445-56. Epub 2007 Feb 27. Review.

PMID:
17327463
[PubMed - indexed for MEDLINE]
Free Article
16.

Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.

Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV.

Pharmacol Rep. 2009 Mar-Apr;61(2):217-24. Review.

PMID:
19443932
[PubMed - indexed for MEDLINE]
Free Article
17.

Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.

Scheen AJ, Paquot N.

Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):103-16. doi: 10.1016/j.beem.2008.09.001. Review.

PMID:
19285264
[PubMed - indexed for MEDLINE]
18.

[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].

Boekholdt SM, Jukema JW, Peters RJ.

Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2615-9. Review. Dutch.

PMID:
18161262
[PubMed - indexed for MEDLINE]
19.

Metabolic syndrome treatment strategies.

Fujioka K.

Pharmacotherapy. 2006 Dec;26(12 Pt 2):222S-226S. Review.

PMID:
17125449
[PubMed - indexed for MEDLINE]
20.

CB1 receptor antagonists: new discoveries leading to new perspectives.

Kirilly E, Gonda X, Bagdy G.

Acta Physiol (Oxf). 2012 May;205(1):41-60. doi: 10.1111/j.1748-1716.2012.02402.x. Review.

PMID:
22463610
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk